about
Climb Bio Inc is a clinical-stage biotechnology company focused on developing therapeutics for patients with immune-mediated diseases. Its pipeline includes Budoprutug, an anti-CD19 monoclonal antibody being developed for B-cell mediated diseases suc...
Read More
13.17
0.59
(4.69%)
654.0K
XNAS Volume
XNAS 17 Jul, 2026 1:57 PM (EDT)
Not Eligible
Expensive Valuation
Technically Bullish
Climb Bio Inc Live Price Chart
Switch to TradingView
Loading Fundamental data..
Loading data..